CJC-1295 with DAC

The DAC modification is a single molecular trick with outsized operational consequences. Understanding why the schedule looks the way it does requires understanding how the molecule lives in the body and what that means for stacking and cycle design.

Why DAC produces continuous rather than pulsatile GHRH stimulation

The maleimide-based DAC tail covalently binds to a free cysteine on circulating albumin within hours of injection. Once bound, the molecule circulates at near-stable plasma concentration for days. This means GHRH receptor occupancy on pituitary somatotrophs is continuous rather than pulsatile — the opposite of the natural pattern of GHRH release. The pituitary response is a chronic, modest GH elevation that drives baseline IGF-1 upward, rather than the sharp pulses of natural GHRH or short-acting analogues.

Stack timing: when to pulse GHRPs against a CJC-1295 background

Because CJC-1295 DAC is always on, the strategic question becomes when to add pulsatile GHRPs (ipamorelin, GHRP-2, GHRP-6) to extract acute GH peaks. The two pathways are synergistic at the somatotroph level. The community-converged schedule is two GHRP pulses per day — pre-bed and pre-workout, or pre-bed and mid-morning fasted — layered onto the once-weekly CJC-1295 background. The combination produces both baseline elevation and acute pulses.

Cycle length and reset cadence

Continuous receptor occupancy raises the same question as any chronic-agonist protocol: at what point does the receptor downregulate? The community consensus is that 12 weeks of continuous DAC dosing followed by a 4-week complete off period preserves response. Longer continuous cycles (16+ weeks) show diminishing returns in user dosing diaries and elevated IGF-1 surveillance flags. The 12-on / 4-off pattern is the operational default.

Timing within the week matters less than schedule consistency. Pick a day, anchor the dose to it, and let the albumin-bound steady state do its work. Mid-week splitting (e.g. Sunday and Wednesday) produces a slightly smoother serum profile than single-day dosing but does not change cumulative effect. For users adding GHRP pulses, time those around food fasting windows regardless of CJC-1295 schedule.

Stack scheduling is the central design question for any CJC-1295 DAC protocol. The albumin-bound steady state is the canvas; daily pulsatile peptides are the brush strokes painted on top.

• CJC-1295 DAC + Ipamorelin (2× daily): Most-used schedule. Weekly DAC for baseline, 200 mcg ipamorelin pre-bed and pre-workout (or AM fasted) for pulses. Pulses converge synergistically on the same somatotroph.
• CJC-1295 DAC + BPC-157: Schedule independence — BPC-157's daily timing does not interfere with DAC's weekly cadence. Common addition for users prioritising recovery alongside GH elevation.
• CJC-1295 DAC + IGF-1 LR3 (advanced): Stacks endogenous IGF-1 (driven by CJC-1295's hepatic effect) with exogenous LR3. Significant cumulative anabolic and IGF-1 load — use with careful monitoring and shorter cycle length.
• CJC-1295 DAC + Tesamorelin (avoid): Both are GHRH receptor agonists. Combining them does not add and may produce receptor downregulation faster than either alone. If switching between them, allow at least a 4-week wash-out.
• Reset cycle solo (no GHRP): For users coming off a heavy stack, a 12-week solo CJC-1295 DAC cycle without GHRPs is a viable maintenance pattern that holds baseline IGF-1 without compounding the pulsatile load.

The schedule itself is the safety control. Continuous baseline IGF-1 elevation — the molecule's defining feature — is also its principal long-term consideration. Periodic IGF-1 measurement is appropriate at cycle midpoint and end. Users with personal or family history of malignancy, particularly hormone-sensitive cancers, should weigh the chronic-elevation profile against the pulsatile alternative (CJC-1295 no-DAC). Site reactions and transient flushing occur in a minority of users; arthralgia and fluid retention are dose-dependent and respond to dose reduction.